DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2002 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: chloroquine phosphate

Summary for Generic Name: chloroquine phosphate

Tradenames:3
Patents:0
Applicants:7
NDAs:9
Drug Master File Entries: see list17
Therapeutic Class:Antiparasitics
Formulation / Manufacturing:see details

Clinical Trials for: chloroquine phosphate

Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Status: Recruiting Condition: Carcinoma, Intraductal, Noninfiltrating; DCIS; Ductal Carcinoma In Situ

A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine
Status: Completed Condition: Malaria

A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
Status: Completed Condition: Malaria Prophylaxis

Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer
Status: Not yet recruiting Condition: Small Cell Lung Cancer

Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients
Status: Recruiting Condition: Small Cell Lung Cancer

Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
Status: Recruiting Condition: Vivax Malaria

Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly
Status: Active, not recruiting Condition: Hyper-reactive Malarial Splenomegaly; Malaria; Anaemia

Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis
Status: Not yet recruiting Condition: Malaria, Falciparum; Chloroquine; Azithromycin; Immunization

Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
Status: Recruiting Condition: Vivax Malaria

Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
Status: Recruiting Condition: Malignant Neoplasm; Solid Tumors

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Sanofi Synthelabo
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
chloroquine phosphate; primaquine phosphate
Tablet; Oral014860Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
Impax Labs
CHLOROQUINE PHOSPHATE
chloroquine phosphate
Tablet; Oral080880Approved prior to Jan 1, 1982RXNo<disabled><disabled>
Md Pharm
CHLOROQUINE PHOSPHATE
chloroquine phosphate
Tablet; Oral087228Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
Purepac Pharm
CHLOROQUINE PHOSPHATE
chloroquine phosphate
Tablet; Oral080886Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc